^
    Back
    Association details:
    Biomarker:BRAF G596V
    Cancer:Lung Adenocarcinoma
    Drug:Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    J Thorac Oncol
    Title:

    Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort

    Excerpt:
    From the 6 patients with non-V600E, one (17%) with G596V had PR with vemurafenib….One patient with G596V achieved PR with vemurafenib.
    DOI:
    10.1097/JTO.0000000000000625